Pediatric Bladder Treatment Market Report 2026

The pediatric bladder treatment market size has grown steadily in recent years. It will grow from $3.72 billion in 2025 to $3.87 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to limited awareness of pediatric bladder disorders, reliance on traditional therapies, lack of specialized pediatric urology centers, limited access to advanced medications, low adoption of digital monitoring tools.

The pediatric bladder treatment market size is expected to see strong growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to growing incidence of pediatric bladder disorders, increasing adoption of advanced treatment modalities, rising investments in pediatric healthcare infrastructure, growing integration of digital health and monitoring solutions, increasing focus on personalized pediatric treatment approaches. Major trends in the forecast period include increasing adoption of advanced urotherapy solutions, rising use of minimally invasive surgical techniques, growing integration of digital health monitoring in pediatric care, increasing demand for targeted pediatric medications, rising focus on personalized treatment plans for pediatric bladder disorders.

The rising prevalence of pediatric bladder disorders is expected to support the growth of the pediatric bladder treatment market in the coming years. Pediatric bladder disorders include a range of medical conditions that affect the normal functioning of the urinary bladder in children. Conditions such as spina bifida and other neurological disorders contribute to urinary complications in pediatric patients, creating a need for effective treatment options. For instance, in March 2023, according to a journal published by the Multidisciplinary Digital Publishing Institute (MDPI), a Switzerland-based publishing company, a study of 1,065 pediatric patients with neurogenic bladder reported that 38.9 percent of patients had spina bifida. The most common complication identified was lower urinary tract infection at 18.1 percent, with a notably higher prevalence among patients with open spina bifida at 54.1 percent. Additionally, during a 12-month follow-up period, frequently observed complications included lower urinary tract infections at 18.1 percent, urinary incontinence at 8 percent, and hydronephrosis at 5.6 percent, while 7.9 percent of patients experienced four or more recurrent lower urinary tract infections. Therefore, the increasing prevalence of pediatric bladder disorders is driving the growth of the pediatric bladder treatment market.

Rising healthcare expenditures are also expected to propel the growth of the pediatric bladder treatment market going forward. Healthcare expenditures represent the total resources spent by individuals, organizations, and governments on healthcare services, products, and infrastructure, including hospital care, physician services, nursing care, and other health-related activities. Healthcare spending is increasing due to factors such as population aging, advancements in medical technology, the growing prevalence of chronic diseases, and rising costs of healthcare services and prescription medications. Higher healthcare expenditure supports the advancement of pediatric bladder treatments by financing research, improving access to advanced therapies, and enabling specialized training for healthcare professionals, thereby enhancing treatment availability and effectiveness. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare spending in the UK increased by 5.6 percent in nominal terms from 2022 to 2023, compared with a 0.9 percent increase in 2022. In 2023, government funding accounted for $309 billion (£239 billion), or 81.9 percent of total healthcare expenditure, making it the largest source of healthcare financing. Therefore, rising healthcare expenditures are contributing to the growth of the pediatric bladder treatment market.

In November 2023, NYU Langone Health, a US-based medical center, acquired Pediatric Urology Associates for an undisclosed amount. Following the acquisition, Pediatric Urology Associates will integrate with NYU Langone, expanding the pediatric urology care team by threefold and adding 10 new practice locations. This integration will also facilitate the implementation of NYU Langone’s Epic electronic health record system, enhancing coordination of patient care. Pediatric Urology Associates is a US-based provider specializing in the treatment of pediatric bladder conditions.

Major companies operating in the pediatric bladder treatment market are Pfizer Inc., F. Hoffmann‑La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Medtronic Plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Astellas Pharma Inc, Cook Medical Inc., Laborie Medical Technologies Corp., Coloplast AIS, UroGen Pharma, Johnson & Johnson, Olympus Corporation, Stryker Corporation, Teleflex Incorporated, B Braun Melsungen AG, Intuitive Surgical Inc, Richard Wolf GmbH, Nipro Corporation, Dornier MedTech, Fresenius Medical Care AG & Co KGaA, Ambu A S, Neuspera Medical, UroMems, Zenflow, Siemens Healthineers, Procter & Gamble.

North America was the largest region in the pediatric bladder treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric bladder treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pediatric bladder treatment market by increasing the cost of imported medical devices, advanced medications, and surgical equipment, particularly affecting North America and Europe. Higher import costs have slowed procurement in hospitals, specialty clinics, and homecare providers. However, tariffs have encouraged local manufacturing of pediatric treatment devices and medications, promoting domestic innovation and cost-efficient solutions in the long term.

The pediatric bladder treatment market research report is one of a series of new reports that provides pediatric bladder treatment market statistics, including pediatric bladder treatment industry global market size, regional shares, competitors with a pediatric bladder treatment market share, detailed pediatric bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric bladder treatment industry. This pediatric bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric bladder disorders encompass a range of medical conditions affecting the urinary bladder in children, including issues that impair bladder function, control, and structure. Pediatric bladder treatment involves the management and treatment of bladder dysfunction, with therapeutic approaches varying based on the child’s age, overall health, medical history, bladder-related symptoms, and the underlying cause of nerve damage or neurological conditions.

The primary types of pediatric bladder disorder treatments include diurnal incontinence, enuresis, and other conditions. Diurnal incontinence refers to the unintentional leakage of urine during daytime hours when bladder control is expected, and treatment in children typically focuses on behavioral and lifestyle interventions. These may include helping the child recognize bladder fullness, promoting scheduled bathroom visits, and managing constipation. Such disorders are also treated using urotherapy, medications, surgical reconstruction, and other therapeutic approaches administered via oral, parenteral, and other routes. Treatment products are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are utilized by end users such as hospitals, homecare settings, specialty clinics, and others.

The pediatric bladder treatment market consists of revenues earned by entities by providing medical consultations, nutritional counseling, catheterization and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric bladder treatment market also includes sales of ultrasound devices, cystoscopes, antibiotics, urinary catheters, incontinence products and surgical instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.